trending Market Intelligence /marketintelligence/en/news-insights/trending/iskmzta0h9gxdkfsoxck6w2 content esgSubNav
In This List

CohBar appoints board member

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


CohBar appoints board member

CohBar Inc. said it appointed Philippe Calais to the board.

Previously, Calais served as the president and CEO of Isarna Therapeutics BV, a developer of oligonucleotide therapeutics.

Menlo Park, Calif.-based CohBar is a biotechnology company focused on the research and development of mitochondria-based therapeutics for age-related diseases.